GB2498543A - Topical prebiotic powder composition and uses thereof - Google Patents
Topical prebiotic powder composition and uses thereof Download PDFInfo
- Publication number
- GB2498543A GB2498543A GB1200858.7A GB201200858A GB2498543A GB 2498543 A GB2498543 A GB 2498543A GB 201200858 A GB201200858 A GB 201200858A GB 2498543 A GB2498543 A GB 2498543A
- Authority
- GB
- United Kingdom
- Prior art keywords
- powder
- prebiotic
- skin
- text
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000843 powder Substances 0.000 title claims abstract description 90
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000000699 topical effect Effects 0.000 title description 3
- 229920001202 Inulin Polymers 0.000 claims abstract description 24
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 22
- 229940029339 inulin Drugs 0.000 claims abstract description 22
- 208000015181 infectious disease Diseases 0.000 claims abstract description 17
- 230000009286 beneficial effect Effects 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 claims abstract description 7
- 230000001594 aberrant effect Effects 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 15
- 150000002482 oligosaccharides Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 61
- 241000894006 Bacteria Species 0.000 description 13
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 13
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 206010012444 Dermatitis diaper Diseases 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 235000012222 talc Nutrition 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 208000002474 Tinea Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000893966 Trichophyton verrucosum Species 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 4
- -1 oligosaccharides) Chemical class 0.000 description 4
- 206010040872 skin infection Diseases 0.000 description 4
- 244000005714 skin microbiome Species 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 244000298479 Cichorium intybus Species 0.000 description 3
- 235000007542 Cichorium intybus Nutrition 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010017543 Fungal skin infection Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 240000008892 Helianthus tuberosus Species 0.000 description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 3
- 208000010195 Onychomycosis Diseases 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000004013 groin Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 201000005882 tinea unguium Diseases 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010072055 Botryomycosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 206010021531 Impetigo Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 241001524190 Kocuria kristinae Species 0.000 description 2
- 241000186684 Lactobacillus pentosus Species 0.000 description 2
- 241000555676 Malassezia Species 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 208000007027 Oral Candidiasis Diseases 0.000 description 2
- 244000215747 Pachyrhizus erosus Species 0.000 description 2
- 235000001591 Pachyrhizus erosus Nutrition 0.000 description 2
- 235000018669 Pachyrhizus tuberosus Nutrition 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001147736 Staphylococcus capitis Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 241000287411 Turdidae Species 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960003913 econazole Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000005005 intertrigo Diseases 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical group O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002607 sulconazole Drugs 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 230000006099 transfructosylation Effects 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- KVEFAMTVBXAETD-LJMGQZPQSA-N (3S,4R,5R)-1-[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3,4,5,6-tetrahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO[C@]1(CO[C@]2(CO[C@]3(CO)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O KVEFAMTVBXAETD-LJMGQZPQSA-N 0.000 description 1
- MMYFQTWHKPSUDE-DLQNOBSRSA-N 1,6-kestotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO[C@@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MMYFQTWHKPSUDE-DLQNOBSRSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N D-fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015216 Erythema marginatum Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000191946 Kytococcus sedentarius Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 235000010804 Maranta arundinacea Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 244000134540 Polymnia sonchifolia Species 0.000 description 1
- 235000003406 Polymnia sonchifolia Nutrition 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000145580 Thalia geniculata Species 0.000 description 1
- 235000012419 Thalia geniculata Nutrition 0.000 description 1
- 241001125847 Tinca Species 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241001473768 Ulmus rubra Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- MMYFQTWHKPSUDE-UHFFFAOYSA-N bifurcose Natural products OC1C(O)C(CO)OC1(CO)OCC1C(O)C(O)C(COC2(CO)C(C(O)C(CO)O2)O)(OC2C(C(O)C(O)C(CO)O2)O)O1 MMYFQTWHKPSUDE-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000002289 effect on microbe Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- UVEIHXHNEIMXTD-VORSWSGSSA-N inulotriose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO[C@]1(CO[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O UVEIHXHNEIMXTD-VORSWSGSSA-N 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A powdered composition for application to the surface of the skin, characterised in that the powder comprises at least one prebiotic, for example inulin and/or alpha glucan oligosaccharide. The composition may be used to stimulate the growth of beneficial microorganisms on the surface of the skin, more preferably, in the treatment or prevention of aberrant infection of the skin or for use as a cosmetic. Also disclosed is a method for producing such a powder composition.
Description
PREBIOTIC POWDER COMPOSITION AND USES THEREOF
This invention relates to prebiotic powder composition and uses thereof, and more particularly the present invention relates to a powder composition which is suitable for applying on to the surface of the skin, said powder comprising at least one prebiotic.
BACKGROUND
Skin including human skin plays a key role in protecting the body from pathogens, and comprises a dermal and an epidermal layer. In its normal healthy state the skin is a host for many different types of microorganisms which do not cause it harm. For example the human skin is generally thought to be covered by beneficial micro-organisms such as Staphylococcus capitis, Coiynebacteriuin xerosis, Micrococcus kristinae and Lactobaciilus acidophilus which together inhabit the complete skin, leaving no place for foreign and hostile organisms.
The beneficial bacteria form a protective anti-bacterial shield against hostile organisms. These beneficial microorganisms exist in a delicate balance. The numbers and identity of the organisms vary between different skin sites. This, together with the skin's structural barrier provides the host with an excellent defence against invading microbes. The number of bacteria on the skin varies from a few hundred per cm2on the arid surfaces of the forearm and back to tens of thousands per cm2 on the moist areas such as the axilla and groin. This normal flora plays an important role in preventing foreign organisms from colonising the skin, but it too needs to be kept in check, in order to avoid skin infections.
When the protective organisms are reduced, their place can be taken by hostile organisms. This can lead to infections and skin irritations for example acne, dandruff and nappy rash. The microbial ecosystem of a healthy individual can be disturbed by the use of antibiotics, during hormonal changes, such as during pregnancy, in people suffering from diabetes, are overweight, have had fungal skin infections in the past, have a weakened immune system caused, for example, by cancer or HIV/AIDS, or the skin has suffered trauma, wound or abrasion, the skin can be subjected to aberrant skin infection in the form of viral infection, fringal infection and bacterial infection. Babies are especially vulnerable to skin irritations, as the beneficial skin flora may not be frilly developed at birth. This is particularly evident in babies born by caesarean section (The bacterial flora of 33 babies at the moment of birth and 410 other new born babies was studied, using a new contact-plate method. Although the skin of babies delivered by csarean section was sterile, the skin of the baby at normal delivery was colonised mainly by non-pathogenic staphylococci and diphtheroid bacilli. ROYAL FREE HOSPITAL, GRAY'S INN ROAD, LONDON W.C.1, Unitcd Kingdom) Non limiting examples of foreign and hostile microorganisms which have been found on the skin include Cant/ic/a albicans, Staphylococcus aureus, Propionibacteriwn acnes and Malassezia Jiujiir. Thcsc and other microorganisms when lcft untreatcd on thc surface of thc skin can form unwantcd skin conditions.
For example common ifingal infections of the skin include Athlete's foot (Tinea pedis and Tinca manuum) which is caused by a combination of fungi and bacteria, causing your skin to become itchy, dry, scaly and red, especially between your toes; Onychomycosis is the name for any fungal nail infection. Tinea unguium (ringworm of your nails) is a common infection; Ringworm of the groin (Tinea cruris) causes an itchy, red rash in your groin and the surrounding area; Ringworm on the body (Tinea corporis), this often affects exposed areas of your body, such as your abdomen (tummy) or your limbs, causing red raised or flat patches and rings that can merge, grow and spread. The rings are scaly at the edge with clear skin at the centre; Intertrigo is a yeast infection of skin folds caused by the fungus Candida albicans, which lives on your skin and in your digestive system; Pityriasis versicolor is a yeast infection which causes dark patches to form on pale or untanned skin and light patches on tanned or darker skin; Thrush (Candida albicans) usually lives in harmony with us and rarely causes problems. However, in certain situations, such as if you're ill, have poorly controlled diabetes, are pregnant or using antibiotics, the fungi multiply and cause problems.
The most common bacteria to cause skin infections are: Staphylococcus aureus which causes conditions such as Folliculitis, Furunculosis (boils), Impetigo, Staphylococcal scalded skin syndrome, and Botryomycosis (pyoderma vegetans); Streptococcus pyogenes which causes Cellulitis, Erysipelas, Impetigo, Necrotising fasciitis, Rheumatic fever, erythema marginatum.
Othcr less common bacterial skin conditions arc for example Haeinophilus species, cause of chancroid and celiulitis in young children; Helicobacterpylori; Klebsiella rhinoscleroinatis, cause of rhino sclcroma.
It is often the case that these conditions are treated with anti-fungal medicines (e.g. clotrimazole, Econazole, ketoconazole, miconazole, sulconazole, nystatin), and/or steroids such as corticostcroids and antibiotics.
Nappy rash is a common condition thought to affect up to a third of nappy-wearing babies at any given time. It causes the baby's skin to become sore and irritated in the area around the nappy, and covered in pink or red spots or blotches. Nappy rash is usually caused by your baby's skin coming into contact with urine and faeces in their nappy and can be a cause of a bacterial or fungal skin infection. Similar problems are associated with juveniles and adults who suffer from incontinence. One commonly used means to prevent infection of the skin where nappy rash is likely to occur is to protect that area of the skin with a barrier cream such as zinc oxide based creams. In more severe cases it may be necessary to treat the condition with medicaments described above.
However, the above treatments all rely on either a skin barrier being formed that prevents infection or the treatment of an infection with an antiseptic or medicament. It is therefore an object of the present invention to provide a composition and treatment methods that will help prevent the growth of aberrant microorganisms on the surface of the skin either before during or post infection.
Prcbiotics are non-digestible food supplements that stimulate the growth andior activity of bacteria in the digestive in ways claimed to be beneficial to health. They were first identified and named by Marcel Roberfroid in 1995 (Dietary modulation of the human colonic microhiota: introducing the concept ofprehiotics. J Nutr. 1995 Jun; 125(6): 1401-12. PMID). Typically, prebiotics are carbohydrates (such as oligosaccharides), but the definition may include non-carbohydrates. The most prevalent forms ofprcbiotics arc nutritionally classed as soluble fiber.
To some extent, many forms of dietary fiber exhibit some level ofprcbiotic effect. Roberfroid offered a refined definition in the 2007 Journal of Nutrition (Prehiotics: The Concept Revisited. J Nutr. 2007; 137: 830S) stating: "A prcbiotic is a selectively fermented ingredient that allows specific changes, both in the composition andior activity in the gastrointestinal microflora that confers benefits upon host well-being and health." As a functional food component, prebiotics, like probiotics, are conceptually intermediate between foods and drugs. Currently the use of prebiotics is confined to dietary use.
Thus the art is deficient in a means of preventing the growth of harmffil microorganisms on the skin by promotion of the growth of beneficial microorganisms on the skin, such beneficial microorganisms out compete the harmful microorganisms.
SUMMARY OF THE INVENTION
An object of the present invention is a powder composition, such as a baby powder or a talc based powder comprising one or more prcbiotics. It is anticipated that application of the prebiotic powder to the surface of the skin will transfer the prebiotic from the powder to the skin.
Advantageously the application of the prebiotic to the skin will stimulate the growth of "friendly" microorganism on the skin, enhancing the beneficial skin flora. Such growth may prevent the growth of non-friendly microorganisms on the skin, or reduce the growth of non-friendly microorganisms by competition between the friendly and non-friendly microorganisms.
Advantageously, such a prebiotic powder would allow an easy means to dry apply the prebiotie to the skin, and would also allow easy storage of prebiotie powder in a powdered form.
A further advantage is that using the powder it is possible to apply the prebiotic either in a highly specific and/or localised way or generally over a large surface area.
In a preferred embodiment the prebiotic is mixed within the base powder to produce a prebiotic powder where the prebiotic is on an accessible surface of the base powder. Advantageously, such a powder would allow for the topical application of the prebiotic to the target skin area wherein the prebiotic would be transferred from the base powder to the surface of the skin In a more preferred embodiment the powder comprises a prebiotic which is a soluble carbohydrate or oligosaeeharide.
In a further preferred embodiment the prebiotic is an inulin or an alpha gluean oligosaceharide.
In the most preferred embodiment the prebiotie comprises about 60% v/v or greater inulin, and about 15% v/v or less alpha glucan oligosaeeharide.
Embodiments of the present invention will now be described in more detail, by way of example only, with reference to and as illustrated by figures 1 to 3 of the drawings: Figure 1: Schematic of process of adding prebiotic to powder. The four stages of the process are (A) prebiotic phase where bulk powder is added to plough trough and mixed when fill, (B) Prebiotie Phase where either dry or liquid prebiotie is added to the trough while the bulk powder is mixing. When liquid prebiotic is used it is placed in a pressurised spray container and liquid prebiotie powder vapour is slowly added to the bulk powder mix, (C) Mixing phase where the powder and prebiotie are mixed further (typically 30 to 60 minutes), and (D) Packaging phase where the mixture is placed in consumer packs.
Figure 2: Structure of A) inulin and B) apha glucan oligosaccharide Figure 3: Structure of skin showing level ofpenetration ofprebiotic powder. A is epidermis laycr (typically 200pm thick), B is the Epidermis (typically 300pm thick), C is the Dermis (typically 1,500gm thick). D indicates the typical level of prebiotic powder penetration Figure 4: Schematic showing application of prebiotic to skin using powder It should also bc noted that ccrtain aspccts of thc drawings are not to scalc and that ccrtain aspects are exemplified or omitted to aid clarity.
EXAMPLE
This invention relates to a powder that is suitable for applying to the surface of the skin to which has been added one or more prebiotics. This powder can be used as Body powder, Baby powder, Facial powder, Sensitive skin powder, Anti-Acne powder, Feminine hygiene powder, Elderly cosmetic powder, Suncare powder or foot powder.
The human skin is susceptible to many different types of aberrant skin infections which include infections by viruses, bacteria and fungi. Such infections can manifest as acne, skin blemishes and rashes. The most common form of skin problcm in young adults is as a result of acne. Acne is when the sebaceous glands in the skin become blocked with sebum. The sebaceous glands and surrounding area can in some instances get infected by bacteria such as P. aenes, P. gramilosurn and members of the stanhvlococcus family. Treatment of infected acne is with antibacterial compounds such as topical benzoyl peroxide, retinoids, antibiotics, or azelaic acid.
Nappy rash causes the baby's skin to become sore and irritated in the area around the nappy, and covered in pink or red spots or blotches. Nappy rash is usually caused by your baby's skin coming into contact with urinc and facces in thcir nappy and can bc a causc of a bacterial or fungal skin infection. Similar problems arc associatcd with juveniles and adults who suffer from incontinent. One commonly used means to prevent infection of the skin where nappy rash is likely to occur is to protect that area of the skin with a barrier cream such as zinc oxide based creams. In more severe cases it may be necessary to treat the condition with medicaments described above.
Other cxamples of bacterial and firngal skin infcctions includc Athletc's foot, Onychomycosis, Ringworm, Intertrigo, Pityriasis vcrsicolor, Thrush, Staphylococcus aurcus, Streptococcus pyogenes, Haemophilus, Helicobacter pylon Kiebsiella rhinoseleromatis.
It is often the case that thcsc conditions are treatcd with anti-fungal mcdicines (e.g. clotrimazolc, Econazole, ketoconazole, miconazole, sulconazole, nystatin), steroids such as corticosteroids and antibiotics.
However, the above treatments all rely on either a skin barrier being formed that prevents infection or the treatment of an infection with an antiseptic or medicament. It is therefore an object of the present invention to provide a composition and treatment methods that wiH hdp prevent the growth of abcrrant microorganisms on the surface of the skin either before during or post infection. The causes which disturb the delicate balance of skin flora are always present. It is not possible to protect the natural balance of skin flora at all times. This is especially the case for babies, elderly people and people with sensitive skin. An effective solution is to make the friendly organisms stronger against important changes/challenges in the skin balance. The organisms can become stronger by a prebiotie ingredient.
A prebiotic is a food supplement for the friendly organism, while the harmful organism (which can cause skin irritations) cannot use the prebiotic as a food supplement. In the presence of a prebiotic, the friendly bacteria will recover and grow faster, whilst the harmful ones are reduced.
The skin problems are reduced in the same time. Prebioties are non-digestible food supplements that stimulate the growth and/or activity of bacteria in ways claimed to be beneficial to health.
Typically, prebiotics are carbohydrates (such as oligosaccharides), but the definition may include non-carbohydrates. The most prevalent forms of prebiotics are nutritionally classed as soluble fiber. Dietary sources of prebiotics include soybeans, inulin sources (such as Jerusalem artichoke, jicama, and chicory root), raw oats, unrefined wheat, unrefined barley and yacon.
Longer-chain prebiotics, e.g. Inulin, contain 9-64 links per saccharidc molecule, and tend to be fermented more slowly, nourishing bacteria predominantly in the left-side colon. Full-spectrum prebiotics provide the full range of molecular link-lengths from 2-64 links per molecule, and nourish bacteria throughout the colon, e.g. Oligofructose-Enriched Inulin (OEI).
The prcbiotic definition does not emphasize a specific bacterial group. Generally, however, it is assumed that a prebiotic should increase the number and/or activity ofbifidobacteria and lactic acid bacteria. Prebiotic oligosaccharides are increasingly added to foods for their health benefits.
Some oligosaccharides that are used in this manner are fructooligosaccharides (FOS), xylooligosaccharides (XOS),polydextrose and galactooligosac charides (GOS). Some monosaccharides such as tagatose are also used Chemically, dietary fiber consists of non-starch polysaccharides such as arabinoxylans, cellulose and many other plant components such as resistant dextrins, inulin, lignin, waxes, chitins, pectins, beta-glucans and oligosaccharidesJ" Inulin is chemically defined as oligosaccharidcs occurring naturally in most plants, inulins have nutritional value as carbohydrates, or more specifically as fructans.polymcrfructosclnulin is typically extracted by manufacturers from chicory roots or Jerusalem artichokes Inulin in the gut promotes an increase in the mass and health of intestinal Lactobacilius and Bifidobacterluin populations.
Fructooligosaccharides (FOS) also sometimes called oligofructose or oligofructan, is a class of oligosaccharides used as an alternative sweetener. The term oligosaccharide refers to a short chain of sugar molecules (in the case of FOS, fructose molecules). Two different classes of fructooligosaccharide (FOS) mixtures are produced commercially, based on inulin degradation or transfructosylation processes.
FOS can be produced by degradation of inulin, or polyfructose, a polymer of D-fructose residues linked by 13(2-> 1) bonds with a terminal a(l -*2) linked D-glucose. The degree ofpolymerization of inulin ranges from 10 to 60. Inulin can be degraded enzymatical ly or chemically to a mixture of oligosaccharides with the general structure Glu-(Fru) (OF1) and Ffllni (Fm), with n and m ranging from 1 to 7. The main components of commercial products arc kcstosc (0F2), nystosc (0F3), fructosylnystosc (GF4), bifurcose (0F3), inulobiosc (F2), inul otriose (F3), and inulotetraose (F4).
The second class of FOS is prepared by the transfructosylation action of a 13-fructosidase of Aspergillus niger on sucrose. The resulting mixture has the general formula of GF, with n ranging from 1 to 5. Contrary to the inulin-derived FOS, not only is there 13(1 -.2) binding but other linkages do occur, however, in limited numbers. In the colon they are fermented by anaerobic bacteria. Fructooligosaccharides are more soluble than inulins and are, therefore, sometimes used as an additive to yoghurt and other (dairy) products.
FOS is extracted from fruits and vegetables such as bananas, onions, chicory root, garlic, asparagus, barlcy, wheat, jIcama, tomatoes, and leeks. The Jerusalem artichoke and its relative yacón have been found to have the highest concentrations of FOS of cultured plants. All inulin-type prebiotics, including FOS, are generally thought to stimulate the growth of Bifidobacteria species. Bi/ldobacteria are considered "friendly bacteria.
Oalacto-oligosaccharides (005), also known as oligogalactosyllactose, oligogalactose, oligolactose or transgalactooligosaccharides (TOS), belong, because of their indigestible nature, to the group of prebiotics. GOS generally comprise a chain of galactose units that arise through consecutive transgalactosylation reactions, with a terminal glucose unit. Commersial derivatives ofGOS include Oligomate 55 in syrup form, Oligomate 5SF in powder fom-i and TOS-100 a purified version of 99% oligosaccharide content syrup (Cup-Oligo 1-170) and powder format (Cup-Oligo P), Vivinal GOS (in a syrup format containing 57% oligosaccharides on dry matter and in a powder format containing 29% oligosaccharides on dry matter), Bimuno, with 52% galacto-oligosaccharidc content on dry matter and syrup.
Mannan-oligosaccharide are widely used in nutrition. MOS has been shown to improve gastrointestinal health as well as overall health, thus improving wellbeing, energy levels and performance. Most MOS products are derived from the cell wall of the yeast, Saccharomyces cerevisiae. MOS has been shown to reduce the prevalence and concentration of different strains of salmonella and E. coli and increase lactobacilli and bifidobacteria in the gut.
Baby powder is usually a mixture of talcum, corn starch and optionally perfumes. The composition will differ based on the type ofbabypowder.
There are purely talcum based baby powders, and there are pure corn starch based baby powders.
The chemical composition of talcum, the formula may be either Mg3Si4OlO(OH)2 or 3MgO.4Si02.HOH, depending on the type of ingredients used.
Composition of talcum powder depends on the company manufacturing the products. Different brands of talcum powder have different composition and so the quality of products. A non-limiting example of what may constitute talcum powder is given below.
* Silicon dioxidc * Magncsium oxidc * Calcium oxide * Iron(III) oxide * Aluminum oxide * Zinc oxide * Bcnzoin * Calcium carbonate Talcum powder ingredients also include organic extracts and essential oils. They are combined with chemicals, having antibacterial and antifungal properties. Clotrimazole is one such compound. Talcum powdcr can contain vitamin E oil and almond oil. Talcum powder for sensitive skin contains arrowroot powder, corn starch, oat starch or tapioca starch. Aloe vera, lavender oil, rose clay, kaolin form a good herbal composition. Talcum powders with kaolin, rose extract, bentonite, myrrh and slippery elm extracts give skin a silky feel.
An embodiment of the present invention is a powder composition suitable for applying to the surface of skin, charaeterised in that the powder comprises at least one prebiotic. The powder composition may be any powder which is suitable for skin contact. However, preferably the powder is a baby powder formulation or a talcum based formulation.
In a preferred embodiment the prebiotic is a carbohydrate or oligosaccharide. In a more preferred embodiment the prebiotic is selected from one or more of the following group: soluble fibre carbohydrate, fructool igosacehari de, galactool igosacharides or man nan ol igosaccharides.
Optionally the prebiotic is selected from one or more of the following: oligofructose (oligofructan), inulin, oligomate 55, oligomate SSp, TOS 100, cup-oligo H70, alpha glucan oligosaccharide, or bimuno, or functional derivatives thereof.
In a more preferred embodiment the prebiotic composition is inulin or alpha glucan oligosaccharide. In a most preferred embodiment the prebiotic composition comprises about 60% v/v or greater inulin, and about 15% v/v or less alpha glucan oligosaccharide. In a preferred option the powder is surface coated with the prebiotic.
In a frirther preferred embodiment the prebiotic comprises a combination of Inulin (>60%), Aqua (25%), Aipha-glucan oligosaccharide (<15%), of vegetable origin.
Metabolisation study show that prebiotics have a diverse effect on microorganisms, for example a: stimulation effect for Saprophytic flora which include, Staphylococcus capitis, Corynehacteriun: xerosis, Micrococcus kristinae, Microcuccus lvlae, Micrococcus sedentarius, Lacto bacillus pentosus, Lactohacillus gasseri, Lactohacillus salivarius, Lactohacillus acidophilus; No stimulation for pathogenic flora such as (andida Alhicans,Gardn crc/la vagina us, Staph viococcus aureus, Staphylococcus epidermis, Staphylococcus hae;noiyticus, (]orvnehacterium minutissimuin, Propionibacterium acnes, Propionihacterium granuioswn, Salmonella choleraesius choleasuis, Salmonella typhimnurium, Escherichia co/i, Malassezia finjimr, and potential inhibiting effect for: S. Aureus c At. kristinae, C. xerostc vc M kritinae, C. aibicans vs L. pentosus.
It is envisaged that the prebiotic is coated onto an accessible surface of the base powder and that the prebiotic is coated onto the powder when the prebiotic is substantially in a liquid phase, said prebiotic being coated bythe following stages: a) Diluting stock prebiotic, with water such that the added water forms up to 25% v/v of the prebiotic composition to form a diluted prebiotic b) Add diluted prebiotic obtained in step a) to the powder at the mixing phase of the powder, at a level of I -5% v/v of the total composition including powder.
c) Mix until even distribution of prebiotic in powder is obtained, d) Optionally add fragrance to a final level of about 0.1% v/v of diluted prebiotic mix.
e) Alternatively, the prebiotic maybe added in a powdered form (at a level of 1 -5% of the total composition including powdcr) to the base powdcr at thc mixing phase of the powder It is envisaged that the powder composition may also be used as a medicament for the treatment of skin disorders or aberrant infections of the skin, as a preventative treatment for skin disorders, or as a cosmetic to be applied to the skin.
It is further envisaged that the described powder could be used in a method of stimulating the growth of beneficial microorganisms on the surface of the skin, said method comprising: a) Applying the powder composition according to the surface of unbroken skin such that the powder forms a contactable layer with the skin, and b) Repeat application when necessary.
It is intended that the claims as filed also form part of the description.
Claims (1)
- <claim-text>Claims 1. A powder composition fbr application to thc surfacc of skin, charactcriscd in that the powder comprises at least one prebiotic.</claim-text> <claim-text>2. The powder composition according to claim 1, characterised in that the powder is a talcum powder, a baby powder or any powder formulation suitable for application to the skin.</claim-text> <claim-text>3. The powder composition according to claim 1 or claim 2, characterised in that the prebiotic is a carbohydrate or oligosaccharide.</claim-text> <claim-text>4. The powder composition according to any one or more of claim 1, claim 2 or claim 3, characterised in that the prebiotic is selected from one or more of the following group: soluble fibre carbohydrate, fructooligosaccharide, galactooligosacharides or mamian ol igosaccharides.</claim-text> <claim-text>5. The powder composition according to any one of the proceeding claims, charactcriscd in that the prebiotic is selected from one or more of the following: oligofructosc (oligofructan), inulin, oligomate 55, oligomate 55p, TOS 100, cup-oligo H70, alpha glucan oligosaccharide, or bimuno, or functional derivatives thereof 6. The powder composition according to any one of the proceeding claims, characterised in that the prebiotic composition is inulin or alpha glucan oligosaccharide.7. The powder composition according to claim 6, characterised in that the prebiotic composition comprises about 60% v/v or greater inulin, and about 15% v/v or less alpha glucan oligosaccharide.8. The powder composition according to claim 7, characterised in that the powder is surface coated with the prebiotic.9. A method of producing a powder comprising one or more prebiotics comprising the stages of; a) Diluting stock prebiotic according to any one of claims 1 to, with water such that the added water forms up to 25% v/v of the prebiotic composition to form a diluted prebiotic b) Add diluted prebiotic obtained in step a) to the powder according to claims 1 and 2 at the mixing phase of the powder, c) Mix until even distribution of prebiotic in powder is obtained, d) Optionally add fragrance to a final level of about 0.1 -2.5% v/v of diluted prebiotic mix.e) Add prebiotic in a powdered form to the powder at the mixing phase of the powder 10. A powder composition according toy one of claims I to 9 for use as a medicament.11. Apowdcrcompositionaccording to anyone of claims 1 to 9 inthcprcparationofa medicament for use in the treatment or prevention of aberrant infection of the skin.12. A powder composition according to any one of claims I to 9 as a cosmetic That is applied to the skin.13. A method of stimulating the growth of beneficial micmorganisms on the surface of the skin, said method comprising: a) Applying the powder composition according to any one of claims Ito 9 to the surface of unbroken skin such that the powder fotms a contactabic layer with the skin, and b) Repeat application when necessaly.14. A composition substantially as described according to the description and drawings herein</claim-text>
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1200858.7A GB2498543A (en) | 2012-01-19 | 2012-01-19 | Topical prebiotic powder composition and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1200858.7A GB2498543A (en) | 2012-01-19 | 2012-01-19 | Topical prebiotic powder composition and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201200858D0 GB201200858D0 (en) | 2012-02-29 |
| GB2498543A true GB2498543A (en) | 2013-07-24 |
Family
ID=45814209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1200858.7A Withdrawn GB2498543A (en) | 2012-01-19 | 2012-01-19 | Topical prebiotic powder composition and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2498543A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITTO20130770A1 (en) * | 2013-09-25 | 2015-03-26 | Paglieri S P A | COMPOSITION BASED ON ACTIVE PREBIOTIC PRINCIPLES FOR THE FORMULATION OF COSMETIC PRODUCTS. |
| WO2015075440A1 (en) * | 2013-11-19 | 2015-05-28 | Aberystwyth University | Prebiotic composition |
| FR3081709A1 (en) * | 2018-05-29 | 2019-12-06 | Lilas 3 | STERILE TOPICAL COMPOSITION FOR USE IN NEWBORNS TO MAINTAIN, REGULATE AND STANDARDIZE CUTANEOUS MICROBIOTE |
| EP3456312A4 (en) * | 2016-05-12 | 2020-01-01 | Natura Cosméticos S.A. | Probiotic cosmetic compositions and use of the probiotic cosmetic compositions |
| WO2020229446A1 (en) * | 2019-05-16 | 2020-11-19 | Unilever N.V. | Use of a sugar or sugar alcohol |
| WO2021110768A1 (en) * | 2019-12-04 | 2021-06-10 | Yodi Sas | Cosmetic cleaning compositions in powder form |
| FR3104025A1 (en) * | 2019-12-04 | 2021-06-11 | Yodi Sas | New cosmetic compositions |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110755345A (en) * | 2019-10-30 | 2020-02-07 | 植物医生(广东)生物科技有限公司 | Prebiotic composition and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110124594A1 (en) * | 2008-07-10 | 2011-05-26 | Alliospharma | Compositions that aim to promote the development and growth of a beneficial vaginal microflora |
-
2012
- 2012-01-19 GB GB1200858.7A patent/GB2498543A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110124594A1 (en) * | 2008-07-10 | 2011-05-26 | Alliospharma | Compositions that aim to promote the development and growth of a beneficial vaginal microflora |
Non-Patent Citations (1)
| Title |
|---|
| WPI Abstract Accession No 2006-173243/18 & DE 102004037505A1 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITTO20130770A1 (en) * | 2013-09-25 | 2015-03-26 | Paglieri S P A | COMPOSITION BASED ON ACTIVE PREBIOTIC PRINCIPLES FOR THE FORMULATION OF COSMETIC PRODUCTS. |
| WO2015075440A1 (en) * | 2013-11-19 | 2015-05-28 | Aberystwyth University | Prebiotic composition |
| US11311029B2 (en) | 2013-11-19 | 2022-04-26 | Aberystwyth University | Prebiotic composition |
| EP3456312A4 (en) * | 2016-05-12 | 2020-01-01 | Natura Cosméticos S.A. | Probiotic cosmetic compositions and use of the probiotic cosmetic compositions |
| FR3081709A1 (en) * | 2018-05-29 | 2019-12-06 | Lilas 3 | STERILE TOPICAL COMPOSITION FOR USE IN NEWBORNS TO MAINTAIN, REGULATE AND STANDARDIZE CUTANEOUS MICROBIOTE |
| WO2020229446A1 (en) * | 2019-05-16 | 2020-11-19 | Unilever N.V. | Use of a sugar or sugar alcohol |
| CN113811357A (en) * | 2019-05-16 | 2021-12-17 | 联合利华知识产权控股有限公司 | Use of sugar or sugar alcohol |
| WO2021110768A1 (en) * | 2019-12-04 | 2021-06-10 | Yodi Sas | Cosmetic cleaning compositions in powder form |
| FR3104025A1 (en) * | 2019-12-04 | 2021-06-11 | Yodi Sas | New cosmetic compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201200858D0 (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2498543A (en) | Topical prebiotic powder composition and uses thereof | |
| You et al. | The promotion mechanism of prebiotics for probiotics: A review | |
| Fei et al. | Role of prebiotics in enhancing the function of next-generation probiotics in gut microbiota | |
| Qiang et al. | Health benefit application of functional oligosaccharides | |
| JP2023022175A (en) | Glycan therapeutics and related methods thereof | |
| Di Bartolomeo et al. | Prebiotics to fight diseases: reality or fiction? | |
| KR102345546B1 (en) | Multi-fiber prebiotic formulation for digestive health, weight control, immune boosting and health improvement | |
| TWI574633B (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| RU2504211C2 (en) | Composition of soluble indigestible fibres and eukaryotic organisms with polysaccharide wall, applicable in health field | |
| Jayachandran et al. | A critical review on diet-induced microbiota changes and cardiovascular diseases | |
| TWI308490B (en) | Use of pullulan as a slowly digested carbohydrate | |
| Koç et al. | The public health rationale for increasing dietary fibre: Health benefits with a focus on gut microbiota | |
| CN104415061B (en) | Edible composition and its production and use | |
| JP2016506381A (en) | Catechin bioavailability enhancer containing cyclodextrin | |
| Terada et al. | Effect of dietary chitosan on faecal microbiota and faecal metabolites of humans | |
| Gao et al. | Impact of prebiotics on enteric diseases and oxidative stress | |
| WO2023220318A2 (en) | Methods for treating urogenital health conditions | |
| JP2009084215A (en) | Inflammatory bowel disease prophylactic or therapeutic agent | |
| WO2014033574A2 (en) | Protein stabilized probiotics and personal care products | |
| Yang et al. | Biological activities and applications of exopolysaccharides produced by lactic acid bacteria: A mini-review | |
| JP2024091787A (en) | Super-oxide dismutase soluble fiber composition | |
| Ravat et al. | Radiation processing of locust bean gum and assessing its functionality for applications in probiotic and enteral foods | |
| JP2006508916A (en) | Branched alpha-glucan for weight management | |
| Baek et al. | Yeast cell wall mannan structural features, biological activities, and production strategies | |
| Sharma et al. | Pre-and probiotics: Using functional foods in the fight against microbial resistance to antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |